These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35542712)

  • 1. Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases.
    Jiang L; Zhang X; Zhou Y; Chen Y; Luo Z; Li J; Yuan C; Huang M
    RSC Adv; 2018 Aug; 8(49):28189-28197. PubMed ID: 35542712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
    Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
    J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
    Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
    Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
    Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-Based Design of Selective Peptidomimetic uPA and TMPRSS2 Inhibitors with Arg Bioisosteres.
    Müller P; Zimmer C; Frey A; Holzmann G; Weldert AC; Schirmeister T
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
    Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
    J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A structural mechanism of flavonoids in inhibiting serine proteases.
    Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
    Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.
    Xue G; Xie X; Zhou Y; Yuan C; Huang M; Jiang L
    Biosci Biotechnol Biochem; 2020 Jun; 84(6):1153-1159. PubMed ID: 32019421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
    Zhou Y; Wu J; Xue G; Li J; Jiang L; Huang M
    Biophys J; 2022 Oct; 121(20):3940-3949. PubMed ID: 36039386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.
    Verner E; Katz BA; Spencer JR; Allen D; Hataye J; Hruzewicz W; Hui HC; Kolesnikov A; Li Y; Luong C; Martelli A; Radika K; Rai R; She M; Shrader W; Sprengeler PA; Trapp S; Wang J; Young WB; Mackman RL
    J Med Chem; 2001 Aug; 44(17):2753-71. PubMed ID: 11495587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
    Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
    J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
    Yang SQ; Craik CS
    J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
    Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
    Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
    Andersen LM; Wind T; Hansen HD; Andreasen PA
    Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
    El Salamouni NS; Buckley BJ; Ranson M; Kelso MJ; Yu H
    Biophys Rev; 2022 Feb; 14(1):277-301. PubMed ID: 35340592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide selectivity between the PDZ domains of human pregnancy-related serine proteases (HtrA1, HtrA2, HtrA3, and HtrA4) can be reshaped by different halogen probes.
    Sun ML; Sun LM; Wang YQ
    J Mol Recognit; 2018 Jun; 31(6):e2698. PubMed ID: 29266444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.